Recent News Releases

Recent News Releases

HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
05 Feb 2020

HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

Now approved by Health Canada: Hizentra®
10 Oct 2018

Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy

Lifesaving Medicines Donated For Patients In The Developing World
12 Apr 2018

Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.

Press Release Archive

If you are interested in global news from CSL Behring, please visit our Global Press Releases.